Study of V540A in healthy women without HPV history
Treatments studied
This trial tests an experimental treatment called V540A in healthy women who have not had HPV. Researchers want to see if it's safe and effective. You may qualify if you have had few sexual partners and no serious health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in generally good health.
- You have had between 0 and 4 sexual partners in your lifetime (any gender).
- You are assigned female at birth, not currently breastfeeding, and will avoid breastfeeding for at least 30 days after the last dose.
- You have no history of severe allergic reactions requiring medical help.
- You have no history of HPV, abnormal cervical biopsy, or HPV-related cancers or lesions.
- You have not received any HPV vaccine or immune-suppressing treatments in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new HPV vaccine (V503, known as Gardasil 9) in Chinese women who either previously received the bivalent HPV vaccine (Cervarix) more than a year ago or never had any HPV vaccine. The goal is to see if this vaccine can effectively prevent HPV-related diseases.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.